Atlas Trials

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Clinical trial NCT04564456 · COMPLETED

Trial details

NCT number
NCT04564456
Sponsor
Respirent Pharmaceuticals Co Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Bioequivalence
Start date
2020-09-22
Primary completion
2020-10-31
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.